1Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Circulation, 2008, 118: 18'94-1909.
3Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention c,f cardiovascular disease. Am J Med, 2011,124: 621-629.
4Sostres C, Gargallo C J, Lanas A. Nonsleroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther, 2013, 15: $3.
5Yeomans ND, Lanas a. I, Talley N J, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther, 205, 22: 795-801.
6Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: Pathobiology, diagnosis, and treatment. J Muhidiscip Heahhc, 2014, 7: 137-146.
7Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol, 2009, 104: 1633-1641.
8Lichtenberger LM, Phan T, Okabe S. Aspirin's ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine. J Physiol Pharmacol, 2011, 62: 491-496.
9Smecuol E, Pinto Sanchez MI, Suarcz A, et aL Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol, '.2009, 7: 524-529.
10Yuhara H, Corley DA, Nakahara F, et al. Aspirin and non-aspirin NSAIDs increase risk of colonic divcrticular bleeding: a systematic review and meta-analysis. J Gastroenterol. 2014, 49: 992-1000.
二级参考文献21
1Cutlip DE. Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007, 115:2344-2351.
2Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of elopidogrel therapy over a 4-year period. Eur Heart J, 2009, 30: 2714-2721.
3Dean J, Yujie Z, Yingxin Z, et al. Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents. Clin Cardiol, 2009.32: 164-168.
4Mollichelli N, Morici N, Ambrogi F, et ah Prolonged double antiplatelet therapy in a cohort of "de novo" diabetic patients treated with drug-eluting stent implantation. Am J Cardiol, 2010, 105: 1395-1401.
5Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coil Cardiol, 2006, 48: 2584-2591.
6Park S J, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med, 2010, 362:1374-1382.
7Collet JP. Silvain J, Barth e 1 e my O, et al. Dual antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet, 2014, 384: 1577-1585.
8Gwon HC. Hahn J Y, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/ pr, unus versus cypher t,, reduce late loss after stenting(EXCELLENT)randomized, muhicenter study. Circulation, 2012, 125:505-513.
9\%lgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multieenter trial. Circulation, 2012, 125: 2015-2026.
10Kim BK, Hong MK, Shin DH, et al. A new strategy fur discontinuation of dual antiplatelet therapy: the RESET Trial. J Am Coil Cardiol, 2012, 60: 1340- 1348.
